新华财经武汉8月7日电(记者郑璐)7日,东阳光药以开创性的“H股吸收合并私有化+介绍上市”模式完成整合上市,正式登陆港交所。在医药行业面临资本寒冬的背景下,东阳光药开辟了一条高效整合的创新路径,并释放多重利好,冲击百亿市场。有业内人士预测,通过吸收合并一体化运作后,东阳光药市值有望突破500亿港元,随着创新药的逐步落地,未来有望成为千亿创新药龙头企业。研产销整合:重塑创新药企价值据了解,作为首单...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.